Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion

摘要

Spindle cell carcinoma (SpCC) is a rare histological type of sarcomatoid carcinoma consisting of spindle-shaped tumor cells. SpCC can occur in many different organs, including the lungs. There is limited data on the clinical presentation, genetic mutant phenotype, treatment, and outcome of lung SpCC. The efficacy of molecular targeted therapy for this tumor is still unclear. Here, we report an adult male with metastatic SpCC harboring a Tropomyosin 3-ROS proto-oncogene 1 ( fusion who showed a long-term response to targeted therapy by crizotinib, a tyrosine kinase inhibitor (TKI).